KDM5D histone demethylase mediates p38α inactivation via its enzymatic activity to inhibit cancer progression
Proceedings of the National Academy of Sciences · 2024
DOI: 10.1073/pnas.2402022121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Jingying Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Joint National Laboratory for Antibody Drug Engineering, The First Affiliated Hospital, School of Medicine, Henan University, Kaifeng 475004, China. Hauptthemen laut MEDLINE: Mitogen-Activated Protein Kinase 14, Lung Neoplasms, Cell Proliferation, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MOST | National Natural Science Foundation of China (NSFC), Henan Provincial Science and Technology Research Project (HPSTRP).
Abstract (Originalsprache)
The p38 MAP kinase (MAPK) signaling pathway plays pivotal roles in various cellular processes. Phosphorylation serves as a canonical way to regulate p38α activation through a phosphorylation cascade. Thus, understanding the mechanism governing p38α phosphorylation is important. The present study demonstrated that p38α undergoes methylation at K165, which promote its phosphorylation in tumor cells. Inhibition of p38α methylation impairs p38α phosphorylation, repressing tumor progression in vitro and in vivo. Mechanistically, KDM5D is a demethylase that interacts with p38α, mediating demethylation at K165 and inhibiting p38α phosphorylation. Moreover, KDM5D is expressed at low levels in non–small cell lung cancer (NSCLC), and high KDM5D expression is positively correlated with cancer survival. KDM5D markedly inhibits cell proliferation and migration via inactivating p38α, thereby slowing cancer progression in xenograft models. In summary, these findings highlight KDM5D as a demethylase of p38α at K165, elucidating a unique role for lysine demethylation in integrating cytoplasmic kinase-signaling cascades. The present results revealed the critical role of KDM5D in suppressing tumor progression, suggesting that KDM5D can serve as a potential drug target for combating hyperactive p38α-driven lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Joint National Laboratory for Antibody Drug Engineering, The First Affiliated Hospital, School of Medicine, Henan University, Kaifeng 475004, China.
- Institute of Translational Medicine, Henan University, Kaifeng 475004, China.
- The First Affiliated Hospital, Henan University, Kaifeng 475004, China.
Förderung
- MOST | National Natural Science Foundation of China (NSFC)
- Henan Provincial Science and Technology Research Project (HPSTRP)
Zitieren
APA
Chen, J., Wang, T., Zhang, D., Wang, H., Huang, Z., Yang, Z., Li, J., Hu, T., Wang, X., & Li, X. (2024). KDM5D histone demethylase mediates p38α inactivation via its enzymatic activity to inhibit cancer progression. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2402022121
Vancouver
Chen J, Wang T, Zhang D, Wang H, Huang Z, Yang Z, et al. KDM5D histone demethylase mediates p38α inactivation via its enzymatic activity to inhibit cancer progression. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2402022121
BibTeX
@article{Chen2024,
author = {Chen, Jingying and Wang, Ting and Zhang, Dongzhe and Wang, Huiling and Huang, Zhiang and Yang, Zhongxin and Li, Jizhuo and Hu, Tianyi and Wang, Xin and Li, Xia},
title = {KDM5D histone demethylase mediates p38α inactivation via its enzymatic activity to inhibit cancer progression},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
doi = {10.1073/pnas.2402022121}
}
EUVIMED